In this on-demand webinar with speaker Dr. Nicholas Ashton, Asst. Professor of Neurochemistry, University of Gothenburg, recent data will demonstrate the ability of p-tau and other blood biomarkers to detect the accumulation of amyloid pathology in asymptomatic individuals. Further, in the symptomatic phase, data will show the capability of p-tau biomarkers (including different epitopes and analytical platforms) to detect Alzheimer's Disease pathology in a heterogenous memory clinic population – which are comparable to clinically validated cerebrospinal fluid (CSF) tests.
You will learn:
Complete the form to access the on-demand webinar and learn more about the development of blood biomarkers that reflect Alzheimer's Disease.